Cairomycin B, a new antibiotic.
Cairomycin B is a new cyclic peptide antibiotic that was isolated from Streptomyces As-C-19 obtained from the soil of Cairo. The antibiotic had the following empirical formula: C(10)H(15)N(3)O(3); on acid hydrolysis, it yielded aspartic acid and lysine. Spectral analysis and its chemical characteristics indicated that it was a cyclic peptide. The antibiotic melted at 120 to 121 degrees C and was freely soluble in chloroform, ethyl acetate, and acetone, slightly soluble in alcohols, and rather insoluble in water and petroleum ether. Cairomycin B was mainly active against gram-positive bacteria, with high toxicity to experimental animals and weak serum-binding properties.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000302:isolation & purification* / Q000494:pharmacology / Q000627:therapeutic use; D023181:Antimicrobial Cationic Peptides; D001419:Bacteria / Q000187:drug effects; D004534:Egypt; D005658:Fungi / Q000187:drug effects; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000096:biosynthesis / Q000302:isolation & purification / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy; D013302:Streptomyces / Q000378:metabolism
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D010456:Peptides, Cyclic; C014377:cairomycin B